⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of NurExone Biologic Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
NurExone Biologic Inc.
↗Toronto, Canada / Haifa, Israel
NurExone Biologic Inc. is a biopharmaceutical company focused on the development and commercialization of regenerative exosome-based therapies for central nervous system (CNS) injuries. Its proprietary ExoTherapy platform utilizes exosome-loaded nanodrugs, which are designed to leverage the natural ability of exosomes to reach damaged or inflamed tissue for targeted delivery of therapeutic compounds.
The company's lead product candidate, ExoPTEN, is being developed for the treatment of acute spinal cord injury and optic nerve damage. NurExone operates with a focus on advancing its pipeline through preclinical validation, CMC (Chemistry, Manufacturing, and Controls) readiness, and regulatory milestones, with the goal of initiating first-in-human clinical trials.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2020
Ownership:public
Status:operating
FUNDING
Stage:Public
STOCK
Exchange:TSXV, OTCQB, FSE
Ticker:NRX, NRXBF, J90
Market Cap:CA$59M
PIPELINE
Stage:Preclinical
Lead Drug Stage:Preclinical (preparing for Phase 1/2a)
Modalities:Exosome therapy, siRNA
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Exo-Top Inc.
Key Partnerships:BioXtek (LOI for manufacturing), Technion - Israel Institute of Technology (Research collaboration)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Lior Shaltiel - CEO
Jacob Licht - Head of U.S. Operations
Yoram Drucker - Chairman
Board Members:Yoram Drucker, Eyal Gabbai
LINKS
Website:nurexone.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with NurExone Biologic Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.